The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation discusses alternatives to minoxidil and finasteride for hair loss, with users expressing skepticism about the effectiveness of Redensyl, Procapil, and Baicapil. One user recommends Finax by Dr. Reddy as a reliable option in India.
The user experienced a diminished orgasm sensation after two days on finasteride. They noted a decrease in sexual drive and slower erections but were most concerned about the lack of climax sensation.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The user applied Kindor's KU, followed by a solution of Finasteride, Minoxidil, and Tretinoin for alopecia. They experienced no side effects from Kindor's KU.
Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."
The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.
Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.
The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.
Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.
A 39-year-old experienced hair regrowth on his temples after switching from finasteride to topical RU58841 combined with 5% minoxidil. He also underwent stem cell treatment and noticed improvements, attributing the regrowth mainly to the change in treatment.
A 35-year-old man underwent a hair transplant with Dr. Patty at HairTran Clinic in Bangkok, receiving 4,037 grafts primarily for his crown area. The procedure cost 188,700 THB, with an additional 12,000 THB for optional PRP treatment, and he plans to update with progress pictures in a year.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Stopping antihistamines may resolve neurological side effects when using finasteride. Users experienced muscle aches, headaches, and lethargy when combining the two.
Two different experiences of using Pyrilutamide, a hair loss treatment, which caused headaches that took around a week to subside in both cases. Other users offered insight into their own experiences with the treatment or suggested alternate treatments such as RU58841 and Minoxidil.
A new hair loss treatment, Pyrilutamide, has been released and is claimed to be a strong anti-androgen, potentially effective when used with finasteride. However, there are mixed opinions on its effectiveness and safety, with some users skeptical and others purchasing it.
The conversation is about the accidental taste of Nizoral shampoo, which contains ketoconazole, during hair washing. Specific hair loss treatments mentioned are Minoxidil, Finasteride, and RU58841.
A user started using RU58841 a month ago after using finasteride and minoxidil for nearly three years, hoping for hair regrowth at the temples. Other users suggest vitamin B supplements and microneedling to improve hair thickness, and one mentions the possibility of a hair transplant for the temples.
A user shared an 8-month update on hair regrowth using HIMS fin/min spray and dermastamping every two weeks, showing significant improvement. Others commented on their own progress and hopes for similar results.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
A user had a positive experience with affordable FUE hair transplants at Harmony Clinic in Cancun, Mexico, noting professionalism and good results despite minor issues. The clinic advised against using Minoxidil and Finasteride, and the user was satisfied with the initial results, planning to update progress at 12 months post-op.
A 24-year-old with mild temple recession is using 5% minoxidil without noticeable effects and has started topical finasteride but is anxious about potential side effects. They are considering a specialist visit for peace of mind despite the cost.
The post discusses the impact of Ashwagandha on hair loss, highlighting its ability to lower stress levels, which is beneficial for hair health. However, there's uncertainty about its potential to increase testosterone and DHT, which could contribute to hair loss.
Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.
The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.